Epigral Limited has informed the Exchange regarding Outcome of Board Meeting held on May 05, 2025.
EPIGRAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.5 pts less than Nifty Microcap 250 and 0.2 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Epigral Limited reported strong FY25 results with standalone revenue from operations rising ~32% to ₹2,550.13 Cr (vs ₹1,929.19 Cr in FY24). Profit after tax surged ~82% to ₹356.70 Cr (vs ₹195.79 Cr), translating to EPS of ₹84.45 (vs ₹47.12). Q4 FY25 revenue stood at ₹627.63 Cr with PAT of ₹86.62 Cr. The Board declared a final dividend of ₹3.50 (35%) per share of face value ₹10. During the year, the company raised ₹333.05 Cr via a QIP at ₹2,093.13 per share, using ₹250 Cr to repay debt, ₹30 Cr for capex, and the rest for general corporate purposes. The statutory auditor SRBC & Co LLP issued an unmodified opinion. EBITDA margin expanded meaningfully as finance costs fell sharply (₹53.27 Cr vs ₹73.49 Cr) on the back of debt reduction.
Strong topline and bottomline growth, falling finance costs from QIP-led deleveraging, and a 35% final dividend should support positive sentiment. The 2-for-15 bonus-like jump in EPS underscores operational leverage, though Q4 sequential decline (PAT down from ₹103.54 Cr in Q3) may temper near-term enthusiasm.